全身18F-FDG PET/CT在初诊鼻窦恶性肿瘤转移筛查中的作用
回顾性分析89例未经治疗的鼻窦恶性肿瘤患者,评估治疗前全身18F-FDG PET/CT筛查远处转移和区域淋巴转移的效用。PET/CT预测远处转移的敏感度和特异度分别为81%和99%,检测区域淋巴转移的敏感度和特异度分别为83%和96%。作者认为全身FDG PET/CT可作为鼻窦肿瘤转移筛查工具并纳入常规治疗前转移评估。
要点
- 远处转移总体频率24%(21/89),PET/CT识别其中81%(17/21)。
- 区域淋巴转移总体频率20%,PET/CT确认其中83%(15/18)。
- 远处转移最常见部位为肺(n=6;28%)和骨(n=5;24%)。
核心结论
- 全身FDG PET/CT可作为鼻窦肿瘤远处转移和区域淋巴转移的筛查工具,并可作为常规治疗前转移评估的一部分。
研究设计与样本
- 回顾性分析纳入2009年1月至2017年8月间89例未经治疗的鼻窦恶性病变患者(女32例、男57例,平均年龄62岁),均行全身FDG PET/CT。
- 以组织病理学分析或随后12个月临床和影像随访作为参考标准,将FDG PET/CT结果与参考标准比较验证。
关键影像表现/征象
- 远处转移按参考标准频率为24%(21/89),其中81%(17/21)由全身FDG PET/CT识别。
- 远处转移最常见部位为肺(n=6;28%)和骨(n=5;24%),其次为肝(n=2;10%)、脑(n=1;5%)和椎管(n=1;5%),6例(28%)存在多部位远处转移。
- 区域淋巴转移按参考标准频率为20%,其中83%(15/18)经FDG PET/CT确认。
诊断标准与关键数值
- FDG PET/CT预测远处转移的敏感度81%(95%CI 62-95%)、特异度99%(95%CI 82-100%)。
- FDG PET/CT检测区域淋巴转移的敏感度83%(95%CI 68-97%)、特异度96%(95%CI 77-100%)。
临床应用与阅片要点
- 作者认为全身FDG PET/CT可用于鼻窦肿瘤远处转移和区域淋巴转移的筛查,并可作为常规治疗前转移评估的一部分。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE. The aim of this study is to assess the utility of pretreatment whole-body 18F-FDG PET/CT in screening for distant metastasis (DM) and regional lymphatic metastasis (LM). MATERIALS AND METHODS. Eighty-nine consecutive patients with untreated sinonasal malignant lesions (32 women and 57 men; mean age, 62 years) underwent whole-body FDG PET/CT between January 2009 and August 2017. A retrospective analysis was performed to determine the presence of DM and LM. Any suspected metastases were confirmed by histopathologic analysis or clinical and imaging follow-up in the subsequent 12 months. The statistics were verified by comparing FDG PET/CT results with a reference standard. RESULTS. Overall, the frequency of DM was 24% (21/89), of which 81% (17/21) were identified by whole-body FDG PET/CT. The sensitivity and specificity of FDG PET/CT in predicting DM were 81% (95% CI, 62-95%) and 99% (95% CI, 82-100%), respectively. The most common DM sites were the lungs (n = 6; 28%) and bones (n = 5; 24%), followed by the liver (n = 2; 10%), brain (n = 1; 5%), and spinal canal (n = 1; 5%), with six patients (28%) having DMs at multiple sites. Overall, the frequency of LM according to the reference standard was 20%, of which 83% (15/18) were confirmed with FDG PET/CT. The sensitivity and specificity of FDG PET/CT in detecting LM were 83% (95% CI, 68-97%) and 96% (95% CI, 77-100%), respectively. CONCLUSION. Our study showed that whole-body FDG PET/CT can be used as a screening tool for the detection of DM and LM in sinonasal neoplasms and could be performed as part of the routine pretreatment evaluation of metastatic workup.
引用
- Ozturk K, Gencturk M, Rischall M, et al. Role of Whole-Body 18F-FDG PET/CT in Screening for Metastases in Newly Diagnosed Sinonasal Malignancies. AJR Am J Roentgenol. 2019. PMID: 30860894. doi:10.2214/AJR.18.20311
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。